Trial Profile
A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Bevacizumab; Docetaxel; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TABEA
- 04 Jun 2013 Interim results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 05 Oct 2012 Status changed from recruiting to discontinued as reported by EudraCT.
- 09 May 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003639).